Рrospects for the use of “dry” carbon dioxide baths in patients with chronic viral hepatitis c with concomitant non-alcoholic fatty liver disease (literature review and own research)
DOI:
https://doi.org/10.12775/JEHS.2020.10.06.036Keywords
chronic viral hepatitis C, non-alcoholic fatty liver disease, antiviral therapy, "dry" carbon dioxide bathsAbstract
The paper analyzes modern views on the etiology, epidemiology, pathogenesis, methods of treating patients with chronic viral hepatitis C with concomitant non-alcoholic fatty liver disease (NAFLD), discusses the possibility of using "dry" carbon dioxide baths (DCDB) in this category of patients. Our research was conducted to study the effectiveness of the integrated use of antiviral therapy (AVT) and DCDB procedures in patients with chronic hepatitis C with concomitant NAFLD. The authors of the study were the first to suggest using of DCDB in this category of patients. Based on the results obtained, for the first time, ideas about the specificity of the DCDBʹs effect on the clinical course of the underlying and concomitant diseases, on the functional state of the liver, the dynamics of lipid metabolism, and ultrasonographic parameters of the liver were detailed. It is concluded that DCDB can be successfully used in the complex treatment of patients with chronic hepatitis C with concomitant NAFLD.
References
Stanaway JD, Flaxman AD, Naghavi M. et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. The Lancet. 2016 Sep 10;388(10049):1081–1088. doi: 10.1016/S0140-6736(16)30579-7.
Bedogni G, Nobili V, Tiribelli C. Epidemiology of fatty liver: an apdate. World J. Gastroenterol. 2014 Jul 21;20(27):9050–9054. doi: 10.3748/wjg.v20.i27.9050.
Zhdanov KV, Kozlov KV, Sukachev VS, Zaharenko SM, Karyakin SS. Elimination of hcv-infection: a history with continuation. J Infectology. 2018;10(4):6–13. doi: 10.22625/2072-6732-2018-10-4-6-13.
Assessment of the viral hepatitis response in Ukraine - WHO. Mission report. 2017 June 6–9. https://www.euro.who.int/__data/assets/pdf_file/0007/372697/ukr-hepatitis-report-eng.PDF?ua=1
Ringehan М, Mc Keating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):20160274. doi: 10.1098/rstb.2016.0274.
Fukui, H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J. Hepatol. 2015 Mar 27;7(3):425–442. doi: 10.4254/wjh.v7.i3.425.
Buzzetti Е, Pinzani М, Tsochatzis EA. The multiple-hit pathogenesis of non-аlcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–1048. doi: 10.1016/j.metabol.2015.12.012.
Kralj D, Jukić LV, ljević SS, Duvnjak М, Smolić М, Čurčić IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol. 2016;4(1):66–75. doi: 10.14218/JCTH.2015.00051.
Satapathy S.K., Sanyal A.J. Epidemiology and natural history of nonalcoholic fatty liver disease. Semin. Liver Dis. 2015;35(3):221–35. doi: 10.1055/s-0035-1562943.
Adinolfi LE, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. International Journal of Molecular Sciences. 2016 Jun;17(6):803. doi: 10.3390/ijms17060803.
Caligiuri A, Gentilini A, Marra F. Molecular pathogenesis of NASH. International Journal of Molecular Sciences. 2016 Sep 20;19(9):1575. doi: 10.3390/ijms17091575.
Jackel-Cram С, Babiuk LA, Liu Q. Up-regulation of Fatty Acid Synthase Promoter by Hepatitis C Virus Core Protein: genotype-3a Core Has a Stronger Effect Than genotype-1b Core. J Hepatol. 2007 Jun;46(6):999–1008. doi: 10.1016/j.jhep.2006.10.019.
Guo CH, Chen PC, Ko WS. Status of Essential Minerals and Oxidative Stressin Viral Hepatitis C Patients with Nonalcoholic Fatty Liver Diseasenternational Journal of Medical Sciences 2013;10(6):730–737. doi: 10.7150/ijms.6104.
Pinzani M. Fatty Liver Disease: co-factor of HCV and evolving disease entity. http://congress-ph.ru/common/htdocs/upload/fm/gepatology/2016/prez/2-1-1.pdf.
Patel A, Harrison SA. Hepatitis C virus infection and nonalcoholic steatohepatitis. Gastroenterology & Hepatology. 2012 May;5(8):305–312. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424424/.
Dulai PS, Singh S, Patel J. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017 May;65(5):1557–1565. doi: 10.1002/hep.29085.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025.
European Association for the Study of the Liver. Electronic address eee.EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–194. doi: 10.1016/j.jhep.2016.09.001.
Bailly F, Pradat P, Virlogeux V, Zoulim F. Antiviral therapy in patients with hepatitis C virus-induced cirrhosis. Dig Dis. 2015;33(4):613–23. doi:10.1159/000375359.
Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: Current and emerging. J Hepatol. 2018 Feb; 68(2):362–75. doi: 10.1016/j.jhep.2017.10.015.
EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J Hepatology. 2016 Jun; 64(6):1388–1402. doi: 10.1016/j.jhep.2015.11.004.
Ezhov VV, Tsarev AY, Platunova TE, Application of dry carbon baths in clinical practice (scientific review). Vestnik Fisioterapii i Kurortologii (Herald of Physiotherapy and Health Resort Therapy). 2017;23(2):63–76. http://science.cfuv.ru/wp-content/uploads/2018/01/VFIK-2-2017.pdf. [in Russian].
Suceveanu M, Suceveanu P, Pop D, Sitar Taut A, Zdrenghea D, Hâncu N. Role of mofette тherapy in cardiovascular rehabilitation – the covasna model. Balneo Research Journal. 2015 May;6(2):69–74. doi: 10.12680/balneo.2015.1089.
Persiianova-Dubrova AL, L'vova NV, Badalov NG. [Carbon Dioxide Baths: State of the Art]. Vopr Kurortol Fizioter Lech Fiz Kult. 2010;(4):48–50. https://pubmed.ncbi.nlm.nih.gov/21089208//
Mayevskaya MV, Ivashkin V.T. Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease/ Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(5):105–116. https://doi.org/10.22416/1382-4376-2018-28-5-105-116. [in Russian].
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 414
Number of citations: 0
